Sign In
Buy ORGO
$2.33
+0.0900 (+4.02%)
At Close: Jun 03, 2026
Organogenesis Holdings Inc. (ORGO) Q2 2025 Earnings Call Transcript
06:30pm, Friday, 08'th Aug 2025
Organogenesis Holdings Inc. (NASDAQ:ORGO ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants David C. Francisco - Chief Financial Officer Gary S.
Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results
04:05pm, Thursday, 07'th Aug 2025
CANTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025
04:05pm, Tuesday, 22'nd Jul 2025
CANTON, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p
CANTON, Mass., July 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p
Organogenesis Holdings: ReNu And New LCD Offer A Rebound Scenario
05:39pm, Monday, 09'th Jun 2025
ORGO's main drivers are its advanced wound-care and surgical biologics that leverage its evidence-rich portfolio. They have a Phase 3 trial on ReNu knee-osteoarthritis with data anticipated by Septemb
Organogenesis Holdings Inc. (ORGO) Q1 2025 Earnings Call Transcript
10:14am, Sunday, 11'th May 2025
Organogenesis Holdings Inc. (NASDAQ:ORGO ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Gary Gillheeney - President and Chief Executive Officer David Francisco - Chief
Organogenesis (ORGO) Reports Q1 Loss, Lags Revenue Estimates
07:10pm, Thursday, 08'th May 2025
Organogenesis (ORGO) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of $0.04. This compares to loss of $0.02 per share a year ago.
Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results
04:05pm, Thursday, 08'th May 2025
CANTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of pr
Burn Care Market worth $3.35 billion by 2030 with 5.6% CAGR | MarketsandMarkets™
10:15am, Friday, 02'nd May 2025
DELRAY BEACH, Fla., May 2, 2025 /PRNewswire/ -- The global Burn Care Market, valued at US$2.46 billion in 2024, is forecasted to grow at a robust CAGR of 5.6%, reaching US$2.55 billion in 2025 and an
Organogenesis recommends CMS also implement an integrated coverage and payment policy Organogenesis recommends CMS also implement an integrated coverage and payment policy
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025
04:05pm, Monday, 07'th Apr 2025
CANTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of
Organogenesis Holdings Inc. (ORGO) Q4 2024 Earnings Call Transcript
08:27pm, Thursday, 27'th Feb 2025
Organogenesis Holdings Inc. (NASDAQ:ORGO ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Gary S. Gillheeney, Sr. – President and Chief Executive Officer Dave Fra
Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results
04:05pm, Thursday, 27'th Feb 2025
CANTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the de
Organogenesis Holdings Inc. to Report Fourth Quarter of Fiscal Year 2024 Financial Results on February 27, 2025
07:30am, Monday, 27'th Jan 2025
CANTON, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of p
